



May 24, 2012

Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy

PITTSBURGH, POTTERS BAR, England and MILAN, May 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its UK and Italy-based subsidiaries have launched Ibandronic Acid Film Coated Tablets POM, 150 mg. This product is the generic version of Roche's Bonviva® Tablets, a treatment for osteoporosis(1).

Mylan CEO Heather Bresch said: "This launch represents another day-one generic for Mylan's businesses in the UK and Italy. We are excited to be adding generic Ibandronic Acid to our strong portfolio of more than 350 products in the UK and 340 products in Italy, as we continue to deliver on our commitment of providing high quality and affordable medicines to patients around the world."

Ibandronic Acid Film Coated Tablets POM had sales of approximately 8.5 million euros (7.5 million pounds Sterling) in the UK and sales of approximately 27 million euros in Italy for the 12 months ending March 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

(1) Treatment of osteoporosis in postmenopausal women at increased risk of fracture. A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.

SOURCE Mylan Inc.

News Provided by Acquire Media